- Home
- CANF vs TNXP Comparison
CANF vs TNXP Comparison
Compare CANF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- TNXP
- Stock Information
- Founded
- CANF 1994
- TNXP 2007
- Country
- CANF Israel
- TNXP United States
- Employees
- CANF N/A
- TNXP N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- TNXP Health Care
- Exchange
- CANF Nasdaq
- TNXP Nasdaq
- Market Cap
- CANF 14.4M
- TNXP 15.1M
- IPO Year
- CANF N/A
- TNXP N/A
- Fundamental
- Price
- CANF $2.46
- TNXP $0.15
- Analyst Decision
- CANF Strong Buy
- TNXP Strong Buy
- Analyst Count
- CANF 2
- TNXP 2
- Target Price
- CANF $14.00
- TNXP $53.50
- AVG Volume (30 Days)
- CANF 137.2K
- TNXP 25.4M
- Earning Date
- CANF 11-15-2024
- TNXP 11-07-2024
- Dividend Yield
- CANF N/A
- TNXP N/A
- EPS Growth
- CANF N/A
- TNXP N/A
- EPS
- CANF N/A
- TNXP N/A
- Revenue
- CANF $667,000.00
- TNXP $12,458,000.00
- Revenue This Year
- CANF $356.93
- TNXP $62.53
- Revenue Next Year
- CANF N/A
- TNXP $26.17
- P/E Ratio
- CANF N/A
- TNXP N/A
- Revenue Growth
- CANF N/A
- TNXP N/A
- 52 Week Low
- CANF $1.81
- TNXP $0.12
- 52 Week High
- CANF $4.69
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- CANF 62.91
- TNXP 35.86
- Support Level
- CANF $1.87
- TNXP $0.13
- Resistance Level
- CANF $2.55
- TNXP $0.18
- Average True Range (ATR)
- CANF 0.17
- TNXP 0.02
- MACD
- CANF 0.06
- TNXP 0.01
- Stochastic Oscillator
- CANF 85.94
- TNXP 30.67
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.